IRON Stock Forecast & Price Target

Disc Medicine is supported by a de-risking pipeline with multiple late-stage catalysts, including bitopertin in EPP/XLP and DBA, DISC-0974 in anemia of MF and CKD, and DISC-3405 in PV and SCD, which broadens upside beyond a single asset. The completed Type A meeting with the FDA clarified that a successful APOLLO readout could anchor the CRL response and potentially support traditional approval, while APOLLO enrollment finished ahead of schedule with 183 patients and topline data expected in 4Q26, followed by a possible mid-2027 FDA decision and 2H27 launch. Disc also has encouraging clinical evidence from DISC-0974, with 55% major hematologic responses in non-transfusion-dependent patients and up to 64% transfusion independence in TD-low patients, reinforcing a credible path to commercialization and a sum-of-parts value supported by 8x multiples on future sales.

Disc Medicine is facing a challenging investment case because its pipeline still depends on clinical execution rather than proven commercial demand, with bitopertin, DISC-0974, and DISC-3405 all carrying meaningful efficacy and toxicity risk. While DISC-3405 showed a clean safety profile in a pooled 38-patient population and a 77.8% maintenance-period result, the 61.5% rate through Week 26 trailed key hepcidin-axis comparators, suggesting the program may not be best-in-class in polycythemia vera. Financially, 2Q showed a $1.54 loss per share, $46.9M of R&D spending, $18.1M of SG&A, and a widened operating loss of $65.1M, even though cash of $717.7M is expected to fund operations through 2029.